| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.YGYNO.2010.01.048 |
| P8608 | Fatcat ID | release_7o5mwjarcffn7o5ozq6acdfzyq |
| P932 | PMC publication ID | 2877379 |
| P698 | PubMed publication ID | 20233625 |
| P5875 | ResearchGate publication ID | 42108701 |
| P2093 | author name string | Michael J Birrer | |
| Kathleen M Darcy | |||
| P2860 | cites work | Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study | Q28258045 |
| Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study | Q83451932 | ||
| Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells | Q28582442 | ||
| A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study | Q30431721 | ||
| Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup | Q30436714 | ||
| Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study | Q30437752 | ||
| Good timing in the cell cycle for precise DNA repair by BRCA1. | Q33221793 | ||
| Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study | Q33331105 | ||
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study | Q33378256 | ||
| Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. | Q35006842 | ||
| Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer | Q35730375 | ||
| Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro | Q36625832 | ||
| Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway | Q37203864 | ||
| Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature | Q37274525 | ||
| Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers | Q37434133 | ||
| High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. | Q40421939 | ||
| Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. | Q40532857 | ||
| Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies | Q40622502 | ||
| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 | ||
| A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study | Q43284690 | ||
| Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study | Q44145129 | ||
| Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study | Q45274595 | ||
| Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study | Q46171137 | ||
| Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study | Q46494607 | ||
| Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study | Q46630310 | ||
| Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study | Q50096089 | ||
| Selective changes in EGF receptor expression and function during the proliferation, differentiation and apoptosis of mammary epithelial cells. | Q52174738 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology G | Q53370060 | ||
| Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. | Q53394047 | ||
| Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. | Q53424963 | ||
| A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. | Q53571352 | ||
| Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. | Q53631355 | ||
| Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer | Q62112715 | ||
| Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study | Q73154720 | ||
| BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study | Q77323363 | ||
| Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study | Q77999242 | ||
| Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 | ||
| Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study | Q79150763 | ||
| Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study | Q80270247 | ||
| Analysis of CHEK2 gene for ovarian cancer susceptibility | Q80600354 | ||
| A role for Ubc9 in tumorigenesis | Q81449663 | ||
| BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study | Q82723058 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| gynecologic oncology | Q5625186 | ||
| P304 | page(s) | 429-439 | |
| P577 | publication date | 2010-03-16 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies | |
| P478 | volume | 117 |
| Q39241466 | Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors |
| Q90697903 | Association between G-protein coupled receptor 4 expression and microvessel density, clinicopathological characteristics and survival in hepatocellular carcinoma |
| Q38401447 | CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis |
| Q36457582 | Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. |
| Q44386340 | DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer |
| Q38392066 | Expression and biological role of cytoglobin in human ovarian cancer |
| Q38402842 | Expression and biological role of δ-catenin in human ovarian cancer |
| Q35674162 | Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer |
| Q42775248 | Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma |
| Q34411194 | Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease |
| Q37332487 | New developments in the treatment of ovarian cancer--future perspectives |
| Q38994527 | Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer |
| Q60934754 | Overexpression of PDK4 is associated with cell proliferation, drug resistance and poor prognosis in ovarian cancer |
| Q35121648 | Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy |
| Q51415152 | Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway. |
| Q34100848 | Whole genome expression profiling of blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14. |
| Q43279631 | microRNA-488 inhibits chemoresistance of ovarian cancer cells by targeting Six1 and mitochondrial function |
Search more.